Douglas Johnson, M.D., M.S.C.I., is associate professor in the Division of Hematology and Oncology at Vanderbilt University Medical Center and leads the Melanoma Clinical Research Program at Vanderbilt-Ingram Cancer Center. His research explores ways to profile cancers to predict which patients will benefit from immune therapies as well as understanding the effectiveness and toxicities of immune therapies in high-risk patients.